BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 11738299)

  • 1. Aspirin impairs reverse myocardial remodeling in patients with heart failure treated with beta-blockers.
    Lindenfeld J; Robertson AD; Lowes BD; Bristow MR;
    J Am Coll Cardiol; 2001 Dec; 38(7):1950-6. PubMed ID: 11738299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of carvedilol on left ventricular remodeling and systolic function in elderly patients with heart failure.
    Palazzuoli A; Bruni F; Puccetti L; Pastorelli M; Angori P; Pasqui AL; Auteri A
    Eur J Heart Fail; 2002 Dec; 4(6):765-70. PubMed ID: 12453548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale and design of the Children's Oncology Group (COG) study ALTE1621: a randomized, placebo-controlled trial to determine if low-dose carvedilol can prevent anthracycline-related left ventricular remodeling in childhood cancer survivors at high risk for developing heart failure.
    Armenian SH; Hudson MM; Chen MH; Colan SD; Lindenfeld L; Mills G; Siyahian A; Gelehrter S; Dang H; Hein W; Green DM; Robison LL; Wong FL; Douglas PS; Bhatia S
    BMC Cardiovasc Disord; 2016 Oct; 16(1):187. PubMed ID: 27716152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction. The carvedilol and ACE-inhibitor remodelling mild heart failure evaluation trial (CARMEN).
    Remme WJ; Riegger G; Hildebrandt P; Komajda M; Jaarsma W; Bobbio M; Soler-Soler J; Scherhag A; Lutiger B; Rydén L
    Cardiovasc Drugs Ther; 2004 Jan; 18(1):57-66. PubMed ID: 15115904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolerability of carvedilol and ACE-Inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN).
    Komajda M; Lutiger B; Madeira H; Thygesen K; Bobbio M; Hildebrandt P; Jaarsma W; Riegger G; Rydén L; Scherhag A; Soler-Soler J; Remme WJ;
    Eur J Heart Fail; 2004 Jun; 6(4):467-75. PubMed ID: 15182773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of carvedilol in patients with impaired left ventricular systolic function following an acute myocardial infarction. How do the treatment effects on total mortality and recurrent myocardial infarction in CAPRICORN compare with previous beta-blocker trials?
    Otterstad JE; Ford I
    Eur J Heart Fail; 2002 Aug; 4(4):501-6. PubMed ID: 12167391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial.
    Cleland JG; Pennell DJ; Ray SG; Coats AJ; Macfarlane PW; Murray GD; Mule JD; Vered Z; Lahiri A;
    Lancet; 2003 Jul; 362(9377):14-21. PubMed ID: 12853194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beneficial effects of carvedilol as a concomitant therapy to angiotensin-converting enzyme inhibitor in patients with ischemic left ventricular systolic dysfunction.
    Gandhi PS; Goyal RK; Jain AR; Mallya BS; Gupta VM; Shah DS; Trivedi BR; Shastri NA; Mehta CB; Jain KA; Bhavasar NS; Shah UJ
    Can J Physiol Pharmacol; 2007 Feb; 85(2):193-9. PubMed ID: 17487260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of bisoprolol fumarate compared with carvedilol in Japanese patients with chronic heart failure: results of the randomized, controlled, double-blind, Multistep Administration of bisoprolol IN Chronic Heart Failure II (MAIN-CHF II) study.
    Hori M; Nagai R; Izumi T; Matsuzaki M
    Heart Vessels; 2014 Mar; 29(2):238-47. PubMed ID: 23559359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of beta-blockers on left ventricular dyssynchrony and reverse remodeling in idiopathic dilated cardiomyopathy: A randomized trial of carvedilol and metoprolol.
    Kaya MG; Sarli B; Akpek M; Kaya EG; Yarlioglues M; Topsakal R; Lam YY
    Cardiol J; 2014; 21(4):434-41. PubMed ID: 24142686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group.
    Lancet; 1997 Feb; 349(9049):375-80. PubMed ID: 9033462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beta-blockade therapy in chronic heart failure: diastolic function and mitral regurgitation improvement by carvedilol.
    Capomolla S; Febo O; Gnemmi M; Riccardi G; Opasich C; Caporotondi A; Mortara A; Pinna GD; Cobelli F
    Am Heart J; 2000 Apr; 139(4):596-608. PubMed ID: 10740140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regression of left ventricular remodeling in chronic heart failure: Comparative and combined effects of captopril and carvedilol.
    Khattar RS; Senior R; Soman P; van der Does R; Lahiri A
    Am Heart J; 2001 Oct; 142(4):704-13. PubMed ID: 11579363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High Dose β-Blocker Therapy Triggers Additional Reverse Remodeling in Patients With Idiopathic Non-Ischemic Cardiomyopathy.
    Nitta D; Kinugawa K; Imamura T; Kato NP; Komuro I
    Int Heart J; 2016 Dec; 57(6):717-724. PubMed ID: 27818482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Bucindolol Investigators.
    Bristow MR; O'Connell JB; Gilbert EM; French WJ; Leatherman G; Kantrowitz NE; Orie J; Smucker ML; Marshall G; Kelly P
    Circulation; 1994 Apr; 89(4):1632-42. PubMed ID: 7908610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of beta-adrenergic receptor gene polymorphisms in the long-term effects of beta-blockade with carvedilol in patients with chronic heart failure.
    Metra M; Covolo L; Pezzali N; Zacà V; Bugatti S; Lombardi C; Bettari L; Romeo A; Gelatti U; Giubbini R; Donato F; Dei Cas L
    Cardiovasc Drugs Ther; 2010 Feb; 24(1):49-60. PubMed ID: 20352314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies).
    Bosch X; Rovira M; Sitges M; Domènech A; Ortiz-Pérez JT; de Caralt TM; Morales-Ruiz M; Perea RJ; Monzó M; Esteve J
    J Am Coll Cardiol; 2013 Jun; 61(23):2355-62. PubMed ID: 23583763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of carvedilol on left ventricular remodelling in chronic stable heart failure: a cardiovascular magnetic resonance study.
    Bellenger NG; Rajappan K; Rahman SL; Lahiri A; Raval U; Webster J; Murray GD; Coats AJ; Cleland JG; Pennell DJ;
    Heart; 2004 Jul; 90(7):760-4. PubMed ID: 15201244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COMPARE: comparison of the effects of carvedilol CR and carvedilol IR on left ventricular ejection fraction in patients with heart failure.
    Greenberg BH; Mehra M; Teerlink JR; Ordronneau P; McCollum D; Gilbert EM
    Am J Cardiol; 2006 Oct; 98(7A):53L-59L. PubMed ID: 17023233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group.
    Circulation; 1995 Jul; 92(2):212-8. PubMed ID: 7600653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.